Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program
Annovis Bio (NYSE: ANVS) announced its participation in the AD/PD™ 2025 conference taking place April 1-5 in Vienna, where they will present comprehensive data from their latest clinical trials.
The company will deliver two key presentations: one focusing on buntanetap's improvements in cognition and motor functions in Phase 3 Parkinson's disease study, and another examining the drug's advantages for APOE4 carriers in Phase 2/3 Alzheimer's disease trials. Additionally, CEO Maria Maccecchini will participate in a forum discussion about novel approaches to biomarkers, imaging, and therapy development.
The presentations schedule includes:
- April 1, 2:45 PM CET: Buntanetap's impact on early Parkinson's patients
- April 2, 9:40 AM CET: APOE4 and buntanetap in Alzheimer's patients
- April 4, 4:20 PM CET: Forum on novel approaches in PD, LBD and MSA pathologies
Annovis Bio (NYSE: ANVS) ha annunciato la sua partecipazione alla conferenza AD/PD™ 2025, che si svolgerà dal 1 al 5 aprile a Vienna, dove presenteranno dati completi dai loro ultimi studi clinici.
L'azienda terrà due presentazioni chiave: una focalizzata sui miglioramenti delle funzioni cognitive e motorie di buntanetap nello studio di Fase 3 sulla malattia di Parkinson, e l'altra che esaminerà i vantaggi del farmaco per i portatori di APOE4 negli studi di Fase 2/3 sulla malattia di Alzheimer. Inoltre, il CEO Maria Maccecchini parteciperà a una discussione in forum su approcci innovativi a biomarcatori, imaging e sviluppo terapeutico.
Il programma delle presentazioni include:
- 1 aprile, 14:45 CET: L'impatto di buntanetap sui pazienti con Parkinson in fase precoce
- 2 aprile, 9:40 CET: APOE4 e buntanetap nei pazienti con Alzheimer
- 4 aprile, 16:20 CET: Forum su approcci innovativi nelle patologie PD, LBD e MSA
Annovis Bio (NYSE: ANVS) anunció su participación en la conferencia AD/PD™ 2025, que se llevará a cabo del 1 al 5 de abril en Viena, donde presentarán datos completos de sus ensayos clínicos más recientes.
La compañía realizará dos presentaciones clave: una centrada en las mejoras de buntanetap en las funciones cognitivas y motoras en el estudio de Fase 3 de la enfermedad de Parkinson, y otra que examinará las ventajas del fármaco para los portadores de APOE4 en los ensayos de Fase 2/3 de la enfermedad de Alzheimer. Además, la CEO Maria Maccecchini participará en un foro de discusión sobre enfoques novedosos para biomarcadores, imágenes y desarrollo terapéutico.
El programa de presentaciones incluye:
- 1 de abril, 14:45 CET: El impacto de buntanetap en pacientes con Parkinson en etapas tempranas
- 2 de abril, 9:40 CET: APOE4 y buntanetap en pacientes con Alzheimer
- 4 de abril, 16:20 CET: Foro sobre enfoques novedosos en patologías de PD, LBD y MSA
안노비스 바이오 (NYSE: ANVS)는 4월 1일부터 5일까지 비엔나에서 열리는 AD/PD™ 2025 컨퍼런스에 참여할 것이라고 발표했으며, 최신 임상 시험의 포괄적인 데이터를 발표할 예정입니다.
회사는 두 가지 주요 발표를 진행할 예정입니다: 하나는 파킨슨병 3상 연구에서 분타네탑의 인지 및 운동 기능 개선에 초점을 맞추고, 다른 하나는 알츠하이머병 2/3상 시험에서 APOE4 보유자를 위한 약물의 장점을 살펴볼 것입니다. 또한, CEO인 마리아 마체키니가 바이오마커, 이미징 및 치료 개발에 대한 새로운 접근 방식에 대한 포럼 토론에 참여할 것입니다.
발표 일정은 다음과 같습니다:
- 4월 1일, 14:45 CET: 초기 파킨슨병 환자에 대한 분타네탑의 영향
- 4월 2일, 9:40 CET: 알츠하이머 환자에서의 APOE4 및 분타네탑
- 4월 4일, 16:20 CET: PD, LBD 및 MSA 병리에 대한 새로운 접근 방식에 대한 포럼
Annovis Bio (NYSE: ANVS) a annoncé sa participation à la conférence AD/PD™ 2025, qui se déroulera du 1er au 5 avril à Vienne, où elle présentera des données complètes de ses derniers essais cliniques.
L'entreprise fera deux présentations clés : l'une se concentrant sur les améliorations de buntanetap en matière de fonctions cognitives et motrices dans l'étude de Phase 3 sur la maladie de Parkinson, et l'autre examinant les avantages du médicament pour les porteurs d'APOE4 dans les essais de Phase 2/3 sur la maladie d'Alzheimer. De plus, la PDG Maria Maccecchini participera à une discussion en forum sur des approches novatrices concernant les biomarqueurs, l'imagerie et le développement thérapeutique.
Le programme des présentations comprend:
- 1er avril, 14h45 CET : L'impact de buntanetap sur les patients atteints de Parkinson à un stade précoce
- 2 avril, 9h40 CET : APOE4 et buntanetap chez les patients atteints d'Alzheimer
- 4 avril, 16h20 CET : Forum sur les approches novatrices dans les pathologies PD, LBD et MSA
Annovis Bio (NYSE: ANVS) gab seine Teilnahme an der AD/PD™ 2025 Konferenz bekannt, die vom 1. bis 5. April in Wien stattfindet, wo sie umfassende Daten aus ihren neuesten klinischen Studien präsentieren werden.
Das Unternehmen wird zwei wichtige Präsentationen halten: eine, die sich auf die Verbesserungen der kognitiven und motorischen Funktionen von buntanetap in der Phase-3-Studie zur Parkinson-Krankheit konzentriert, und eine andere, die die Vorteile des Medikaments für APOE4-Träger in Phase-2/3-Studien zur Alzheimer-Krankheit untersucht. Darüber hinaus wird CEO Maria Maccecchini an einer Forum-Diskussion über neuartige Ansätze zu Biomarkern, Bildgebung und Therapieentwicklung teilnehmen.
Der Zeitplan für die Präsentationen umfasst:
- 1. April, 14:45 CET: Die Auswirkungen von buntanetap auf frühe Parkinson-Patienten
- 2. April, 9:40 CET: APOE4 und buntanetap bei Alzheimer-Patienten
- 4. April, 16:20 CET: Forum über neuartige Ansätze bei PD, LBD und MSA-Pathologien
- None.
- None.
MALVERN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its participation in the AD/PD™ 2025 taking place April 1-5 in Vienna.
"We are at a pivotal moment in our company’s journey as we have entered the late clinical stages for both Alzheimer’s and Parkinson’s. It is incredibly rewarding to see our work bring us here, once again supporting that our drug is efficacious and safe across both indications,” commented Maria Maccecchini, Ph.D., Founder and CEO of Annovis. “At this meeting, we will present comprehensive data from our latest Phase 3 PD and Phase 2/3 AD studies. For Parkinson’s, we will take a deeper look into the cognitive response, while for Alzheimer’s, we will dive into the advantages of buntanetap for APOE4 carriers, addressing a pressing challenge in existing AD therapies."
Annovis will give two presentations and participate in a forum discussion:
Presentation: BUNTANETAP IMPROVES EARLY PARKINSON’S PATIENTS’ COGNITION AND MOTOR FUNCTIONS IN A PHASE 3 STUDY
- Date: April 1
- Time: 2:45 – 3:00 pm CET
- Presenter: Maria Maccecchini, Ph.D., Founder and CEO
Presentation: APOE4 AND BUNTANETAP IN PHASE II/III ALZHEIMER’S PATIENTS
- Date: April 2
- Time: 9:40 – 9:55 am CET
- Presenter: Cheng Fang, Ph.D., SVP, Research and Development
Forum: NOVEL APPROACHES TO ACCELERATE DEVELOPMENT OF BIOMARKERS, IMAGING, AND THERAPY OF ALPHA-SYNUCLEIN, LRKK2, AND GBA PATHOLOGIES LINKED TO PD, LBD AND MSA
- Date: April 4
- Time: 4:20 – 5:20 pm CET
- Participant: Maria Maccecchini, Ph.D., Founder and CEO
The AD/PD™ 2025 conference brings together the brightest minds in the field in order to share the latest breakthroughs in treatment, translational R&D, early diagnosis, drug development and clinical trials in AD, PD, and other related neurological disorders.
About Annovis
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at https://www.annovisbio.com/email-alerts.
Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com
FAQ
What clinical trial results will Annovis Bio (ANVS) present at AD/PD 2025?
When and where will Annovis Bio (ANVS) present at AD/PD 2025?
What is buntanetap's potential impact on APOE4 carriers with Alzheimer's?
How is Annovis Bio (ANVS) advancing their Parkinson's disease treatment?
What neurodegenerative conditions is Annovis Bio (ANVS) targeting with buntanetap?
